Type 2 & other diabetes

Impact of the timing of metformin administration on glycaemic and glucagon-like peptide-1 responses to intraduodenal glucose infusion in type 2 diabetes: a double-blind, randomised, placebo-controlled, crossover study

DiabetologiaPublished Randomised controlled trial

Authors' conclusion

In well-controlled metformin-treated type 2 diabetes, glucose-lowering by metformin is greater when it is given before, rather than with, enteral glucose, and this is associated with a greater GLP-1 response. These observations suggest that administration of metformin before meals may optimise its effect in improving postprandial glycaemic control.

Study context

Population
Individuals with T2D relatively well-controlled by metformin monotherapy; intraduodenal glucose infusion 12.56 kJ/min (3 kcal/min) at t = 0–60 mincrossover, 4 study days
Participants
16 individuals
Comparison
Intraduodenal metformin at t = −60, −30 or 0 min vs saline (control) before intraduodenal glucose infusion
Methodological detailsdouble-blind, placebo-controlled, crossover
  • Double-blind
  • Placebo-controlled
  • Crossover

Primary result

As reported in the abstract

Plasma glucose, GLP-1 and insulin responses · t = -60 to 120 min
Treatment-by-time interaction for metformin in reducing plasma glucose and increasing plasma GLP-1 and insulin
p<0.05 for each
Greater reduction in plasma glucose with metformin at t = −60 or −30 min vs t = 0 min
p<0.05 for each
Increases in plasma GLP-1 evident only with metformin at t = −60 or −30 min
p<0.05 for each

Further findings

Metformin enhanced glucose-induced insulin secretion
P < 0.05
Metformin did not influence insulin sensitivity
Increases in plasma insulin comparable on the 3 metformin days

Original publication

Impact of the timing of metformin administration on glycaemic and glucagon-like peptide-1 responses to intraduodenal glucose infusion in type 2 diabetes: a double-blind, randomised, placebo-controlled, crossover study. Diabetologia. Published 1 April 2024. doi:10.1007/s00125-024-06131-6

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.